Karen Prange
CIK 1566083 · EVP&CEO Gl.AH.Med.Den.Sur.Grp · last filed 2026-08-07
Karen Prange is an EVP&CEO Gl.AH.Med.Den.Sur.Grp who has filed 62 SEC Form 4 insider transactions across 8 companies since 2013. The most recent filing shows the insider sold $138.3K of ATRC on Aug 7, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.5M across reported positions. 21 SEC filings were submitted jointly with BOSTON SCIENTIFIC CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BSX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
FORT LAUDERDALE, FL 33316
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATRC | Director | 22,809 | $61.08 | $1.39M | -$629.2K | 13 | 2026-08-07 |
| OM | Director | 29,334 | $4.08 | $119.7K | $0 | 2 | 2026-06-05 |
| EMBC | Director | 64,581 | $6.80 | $439.2K | $0 | 5 | 2026-02-13 |
| NEVRO CORP (NVRO) Delisted | Director | 0 | $5.84 | $0 | $0 | 6 | 2025-04-03 |
| ViewRay, Inc. (VRAY) Delisted | Director | 46,399 | $0.03 | $1.2K | $91.2K | 5 | 2023-07-21 |
| CANTEL MEDICAL CORP (CMD) Delisted | Director | 0 | $80.37 | $0 | $0 | 2 | 2021-06-02 |
| HSIC | EVP&CEO Gl.AH.Med.Den.Sur.Grp | 80,200 | $84.51 | $6.78M | $0 | 3 | 2018-03-06 |
| BSX | SVP&Pres, Uro & Pelvic Health | 39,395 | $45.58 | $1.80M | -$976.2K | 20 | 2016-03-08 |
Recent Filings
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-07 | ATRC | Sell (S) | −3,564 | -$138.3K | EDGAR |
| 2026-08-07 | ATRC | Sell (S) | −3,564 | -$138.3K | EDGAR |
| 2026-08-05 | ATRC | Notice (144) | −3,564 | -$139.0K | EDGAR |
| 2026-06-05 | OM | Grant (A) | +10,667 | $0 | EDGAR |
| 2026-05-22 | ATRC | Sell (S) | −3,000 | -$86.0K | EDGAR |
| 2026-05-20 | ATRC | Notice (144) | −3,000 | -$86.4K | EDGAR |
| 2026-05-20 | ATRC | Grant (A) | +6,144 | $0 | EDGAR |
| 2026-02-13 | EMBC | Grant (A) | +22,841 | $0 | EDGAR |
| 2026-01-12 | OM | Grant (A) | +18,667 | $0 | EDGAR |
| 2025-05-21 | ATRC | Grant (A) | +5,401 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.